Sameek Roychowdhury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sameek Roychowdhury has a total of 452 co-authors. Here are the top co-authors by number of shared publications:
Eric Samorodnitsky
The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
24 shared publicationsJulie W. Reeser
Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, USA
22 shared publications- Milind Javle
The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
20 shared publications - Adam Diehl
Department of Gastrointestinal Medical Oncology, University of Washington School of Medicine, Seattle, Washington
19 shared publications - Alex Rajewski
Cedars-Sinai Med Cntr, Los Angeles, CA
19 shared publications - Annie Blair Richardson
Cure First, Bothell, Washington
19 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Phase 2 basket trial of ponatinib in tumors with FGFR alterations and other genomic targets
- 6 November 2026
- Published by Springer Nature in BMC Cancer
Open AccessPhase 2 basket trial of ponatinib in tumors with FGFR alterations and other genomic targets
- Open Access
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
GemSarc: A Novel Predictive Gene Signature for Gemcitabine Efficacy in Advanced Bone and Soft Tissue Sarcomas
Purpose: There are no validated predictive biomarkers for chemotherapy response in advanced soft-tissue sarcoma. We sought to develop and validate an RNA-based gene signature predictive of gemcitabine response. Methods: Patients treated with gemcitabine-based chemotherapy were identified from The Ohio State University (OSU) Sarcoma Registry (ClinicalTrials.gov identifier: NCT02677961 ). Responders were defined as patients with a time to gemcitabine discontinuation greater than the cohort median, based on RECIST-defined progression. Gene expression from Tempus RNA sequencing data was correlated with gemcitabine half maximal inhibitory concentration from sarcoma cell lines to identify predictive transcripts. Differentially expressed genes between responders and nonresponders were intersected, and a random forest regression model was trained to generate the GemSarc score. The model was externally validated using Oncology Research Information Exchange Network (ORIEN) and Total Cancer Care (TCC) data sets. Results: Thirty-one patients met inclusion criteria. Unsupervised clustering revealed three transcriptomic subgroups, with prolonged duration of therapy in clusters enriched for DNA replication and repair pathways. The GemSarc model identified 19 genes that predicted gemcitabine sensitivity. High GemSarc scores were associated with improved clinical benefit in the OSU discovery cohort (hazard ratio [HR], 0.23 [95% CI, 0.08 to 0.66]), with consistent validation in two independent cohorts (ORIEN: HR, 0.30; TCC: HR, 0.17). The model also demonstrated strong discriminatory performance, with AUCs of 0.88 and 0.79 in the ORIEN and TCC cohorts, respectively. GemSarc did not predict overall survival or progression-free survival in patients with sarcoma from The Cancer Genome Atlas data. GemSarc also failed to identify responders to other cytotoxic agents (AUC <0.63). Conclusion: GemSarc is a validated RNA-based predictive biomarker that identifies patients with advanced sarcomas likely to benefit from gemcitabine-based therapy. Its implementation may optimize patient selection and guide biomarker-driven clinical trials in sarcoma.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Open AccessGemSarc: A Novel Predictive Gene Signature for Gemcitabine Efficacy in Advanced Bone and Soft Tissue Sarcomas
Purpose: There are no validated predictive biomarkers for chemotherapy response in advanced soft-tissue sarcoma. We sought to develop and validate an RNA-based gene signature predictive of gemcitabine response. Methods: Patients treated with gemcitabine-based chemotherapy were identified from The Ohio State University (OSU) Sarcoma Registry (ClinicalTrials.gov identifier: NCT02677961 ). Responders were defined as patients with a time to gemcitabine discontinuation greater than the cohort median, based on RECIST-defined progression. Gene expression from Tempus RNA sequencing data was correlated with gemcitabine half maximal inhibitory concentration from sarcoma cell lines to identify predictive transcripts. Differentially expressed genes between responders and nonresponders were intersected, and a random forest regression model was trained to generate the GemSarc score. The model was externally validated using Oncology Research Information Exchange Network (ORIEN) and Total Cancer Care (TCC) data sets. Results: Thirty-one patients met inclusion criteria. Unsupervised clustering revealed three transcriptomic subgroups, with prolonged duration of therapy in clusters enriched for DNA replication and repair pathways. The GemSarc model identified 19 genes that predicted gemcitabine sensitivity. High GemSarc scores were associated with improved clinical benefit in the OSU discovery cohort (hazard ratio [HR], 0.23 [95% CI, 0.08 to 0.66]), with consistent validation in two independent cohorts (ORIEN: HR, 0.30; TCC: HR, 0.17). The model also demonstrated strong discriminatory performance, with AUCs of 0.88 and 0.79 in the ORIEN and TCC cohorts, respectively. GemSarc did not predict overall survival or progression-free survival in patients with sarcoma from The Cancer Genome Atlas data. GemSarc also failed to identify responders to other cytotoxic agents (AUC <0.63). Conclusion: GemSarc is a validated RNA-based predictive biomarker that identifies patients with advanced sarcomas likely to benefit from gemcitabine-based therapy. Its implementation may optimize patient selection and guide biomarker-driven clinical trials in sarcoma.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table S4. Drugs tested for each tumor organoid culture.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table S4. Drugs tested for each tumor organoid culture.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Brightfield images of BTC organoid cultures
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Brightfield images of BTC organoid cultures
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Clinical characteristics of the BTC cohort
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Clinical characteristics of the BTC cohort
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table 3. Cholangiocarcinoma genomic landscape from The Cancer Genome Atlas (TCGA) and comparison to this BTC cohort.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table 3. Cholangiocarcinoma genomic landscape from The Cancer Genome Atlas (TCGA) and comparison to this BTC cohort.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Tumor organoid confirmation by comparison to third party genomics of the primary tumor
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Tumor organoid confirmation by comparison to third party genomics of the primary tumor
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Biliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid–based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments–certified PARIS assay. Despite most organoids being from late-stage disease, 24/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with known genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFR-BICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and >8-month survival. Significance:Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Biliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid–based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments–certified PARIS assay. Despite most organoids being from late-stage disease, 24/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with known genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFR-BICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and >8-month survival. Significance:Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Pharmacotype of BTC organoids. A, Heatmap showing PARIS assay results for all targeted drugs tested in at least five organoid cultures. B, Heatmap showing PARIS assay results for all chemotherapeutic agents tested in at least one organoid culture. White rectangles indicate drugs that were not tested in that screen. Asterisks next to a patient number indicate that the drug screen failed some parameter of quality control but was still evaluable.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Pharmacotype of BTC organoids. A, Heatmap showing PARIS assay results for all targeted drugs tested in at least five organoid cultures. B, Heatmap showing PARIS assay results for all chemotherapeutic agents tested in at least one organoid culture. White rectangles indicate drugs that were not tested in that screen. Asterisks next to a patient number indicate that the drug screen failed some parameter of quality control but was still evaluable.